Arcadia Biosciences (NASDAQ:RKDA) Issues Quarterly Earnings Results

Arcadia Biosciences (NASDAQ:RKDA) posted its quarterly earnings results on Thursday. The basic materials company reported ($2.11) EPS for the quarter, missing the consensus estimate of ($0.80) by ($1.31), FiscalAI reports. Arcadia Biosciences had a negative net margin of 195.94% and a negative return on equity of 102.73%. The business had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $1.60 million.

Arcadia Biosciences Stock Performance

Shares of Arcadia Biosciences stock opened at $0.96 on Friday. The firm has a 50-day simple moving average of $1.39 and a two-hundred day simple moving average of $2.32. The company has a market cap of $1.97 million, a P/E ratio of -0.17 and a beta of 0.52. Arcadia Biosciences has a fifty-two week low of $0.89 and a fifty-two week high of $6.71.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Arcadia Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.